Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Final phase 2 results of LCL161 for myelofibrosis

At the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, the final results of phase 2 trial of LCL161 for myelofibrosis (MF) were presented by Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX. Here Dr Pemmaraju discusses the findings from the use of this novel oral SMAC mimetic/IAP antagonist in intermediate to high-risk MF (NCT02098161).